Business Description
Nanjing Hicin Pharmaceutical Co Ltd
ISIN : CNE100002F44
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.13 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.29 | |||||
Debt-to-EBITDA | 5.44 | |||||
Interest Coverage | 7.47 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 5.08 | |||||
Beneish M-Score | -2.47 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -9.8 | |||||
3-Year EBITDA Growth Rate | -0.2 | |||||
3-Year EPS without NRI Growth Rate | -11.3 | |||||
3-Year FCF Growth Rate | -54.8 | |||||
3-Year Book Growth Rate | 13.3 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 31.64 | |||||
9-Day RSI | 36.9 | |||||
14-Day RSI | 41.6 | |||||
6-1 Month Momentum % | 42.39 | |||||
12-1 Month Momentum % | -3.76 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.05 | |||||
Quick Ratio | 0.78 | |||||
Cash Ratio | 0.12 | |||||
Days Inventory | 349.66 | |||||
Days Sales Outstanding | 140.75 | |||||
Days Payable | 257.47 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.23 | |||||
Dividend Payout Ratio | 0.13 | |||||
Forward Dividend Yield % | 0.23 | |||||
5-Year Yield-on-Cost % | 0.24 | |||||
Shareholder Yield % | -2.65 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 82.34 | |||||
Operating Margin % | 12.64 | |||||
Net Margin % | 8.4 | |||||
FCF Margin % | -13.68 | |||||
ROE % | 4.22 | |||||
ROA % | 3 | |||||
ROIC % | 4.53 | |||||
ROC (Joel Greenblatt) % | 6.22 | |||||
ROCE % | 5.16 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 59.34 | |||||
PE Ratio without NRI | 51.93 | |||||
Shiller PE Ratio | 26.63 | |||||
PS Ratio | 4.96 | |||||
PB Ratio | 2.47 | |||||
Price-to-Tangible-Book | 2.93 | |||||
Price-to-Operating-Cash-Flow | 51.57 | |||||
EV-to-EBIT | 52.6 | |||||
EV-to-EBITDA | 52.6 | |||||
EV-to-Revenue | 5.61 | |||||
EV-to-FCF | -43.68 | |||||
Price-to-Projected-FCF | 15.39 | |||||
Price-to-Graham-Number | 2.6 | |||||
Earnings Yield (Greenblatt) % | 1.9 | |||||
FCF Yield % | -2.75 | |||||
Forward Rate of Return (Yacktman) % | -19.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Nanjing Hicin Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 500.382 | ||
EPS (TTM) (Â¥) | 0.35 | ||
Beta | 0.03 | ||
Volatility % | 56.3 | ||
14-Day RSI | 41.6 | ||
14-Day ATR (Â¥) | 0.874029 | ||
20-Day SMA (Â¥) | 22.099 | ||
12-1 Month Momentum % | -3.76 | ||
52-Week Range (Â¥) | 12.68 - 27.93 | ||
Shares Outstanding (Mil) | 120 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Nanjing Hicin Pharmaceutical Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Nanjing Hicin Pharmaceutical Co Ltd Stock Events
Event | Date | Price(Â¥) | ||
---|---|---|---|---|
No Event Data |
Nanjing Hicin Pharmaceutical Co Ltd Frequently Asked Questions
What is Nanjing Hicin Pharmaceutical Co Ltd(SZSE:300584)'s stock price today?
When is next earnings date of Nanjing Hicin Pharmaceutical Co Ltd(SZSE:300584)?
Does Nanjing Hicin Pharmaceutical Co Ltd(SZSE:300584) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |